Pfizer is working to deal with typical business issues in the drug space, but its attempt at a solution has become very complicated.

The first thing that comes to mind when we speak about the S&P 500 is the biggest tech companies, high valuations, and ...

The bidding war between Pfizer ( PFE) and Novo Nordisk ( NVO) over obesity drug developer Metsera ( MTSR) finally ended over ...

As you might expect, the competition to win a share of the expanding GLP-1 market is fierce right now, with giants Novo ...

Concerns about the company's future growth are likely keeping investors away.

Wendy’s plans to close hundreds of US restaurants over the next few months in an effort to boost its profit. The Dublin, Ohio ...

Pfizer Wins Battle for Weight-Loss Drugmaker Metsera. Why Novo Nordisk Is the Real Winner.

Pfizer has fended off Nova Nordisk for control of the next-gen weight-loss drug developer Metsera. Meanwhile, Resmed watches ...

Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

Here are some of the stocks making notable moves in Monday's premarket action: TreeHouse Foods shares are surging 19% after the food and beverage company agreed to be taken private by Industrial F&B ...

Metsera shares fell significantly as the firm accepted a $10 billion offer from Pfizer, ending its bidding war with Novo Nordisk. Despite the dip, Metsera shares have surged since Pfizer's initial ...